Dabrafenib mesylate: Difference between revisions

Dabrafenib mesylate
	Adult Indications & Dosage
	Pediatric Indications & Dosage
	Contraindications
	Warnings & Precautions
	Adverse Reactions
	Drug Interactions
	Use in Specific Populations
	Administration & Monitoring
	Overdosage
	Pharmacology
	Clinical Studies
	How Supplied
	Images
	Patient Counseling Information
	Precautions with Alcohol
	Brand Names
	Look-Alike Names

VisualWikitext

Revision as of 18:02, 30 January 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Dabrafenib mesylate is a BRAF Inhibitor that is FDA approved for the treatment of malignant melanoma. Common adverse reactions include peripheral edema, alopecia, hyperkeratosis, abdominal pain, constipation, anemia, arthralgia, cough.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

BRAF V600E Mutation-Positive Unresectable or Metastatic Melanoma

TAFINLAR® as a single agent is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma

TAFINLAR, in combination with trametinib, is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test. This indication is based on the demonstration of durable response rate [see Clinical Studies (14.2)]. Improvement in disease-related symptoms or overall survival has not been demonstrated for TAFINLAR in combination with trametinib.

Limitation of Use

TAFINLAR is not indicated for treatment of patients with wild-type BRAF melanoma.

Dosing

Recommended Dosing

The recommended dosage regimens of TAFINLAR are:

150 mg orally taken twice daily, approximately 12 hours apart, as a single agent

150 mg orally taken twice daily, approximately 12 hours apart, in combination with trametinib 2 mg orally taken once daily

Continue treatment until disease progression or unacceptable toxicity occurs. Take TAFINLAR as a single agent, or TAFINLAR in combination with trametinib, at least 1 hour before or 2 hours after a meal[see Clinical Pharmacology (12.3)]. Do not take a missed dose of TAFINLAR within 6 hours of the next dose of TAFINLAR. Do not open, crush, or break TAFINLAR capsule.

When administered in combination with trametinib, take the once-daily dose of trametinib at the same time each day with either the morning dose or the evening dose of TAFINLAR.

Dose Modifications

For New Primary Cutaneous Malignancies: No dose modifications are required.

For New Primary Non-Cutaneous Malignancies: Permanently discontinue TAFINLAR in patients who develop RAS mutation-positive non-cutaneous malignancies. If used in combination with trametinib, no dose modifications are required for trametinib in patients who develop non-cutaneous malignancies.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Dabrafenib mesylate in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Dabrafenib mesylate in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Dabrafenib mesylate in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Dabrafenib mesylate in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Dabrafenib mesylate in pediatric patients.

Contraindications

There is limited information regarding Dabrafenib mesylate Contraindications in the drug label.

Warnings

There is limited information regarding Dabrafenib mesylate Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Dabrafenib mesylate in the drug label.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Dabrafenib mesylate in the drug label.

Drug Interactions

There is limited information regarding Dabrafenib mesylate Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Dabrafenib mesylate in women who are pregnant.
Pregnancy Category (AUS):

Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Dabrafenib mesylate in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Dabrafenib mesylate during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Dabrafenib mesylate with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Dabrafenib mesylate with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Dabrafenib mesylate with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Dabrafenib mesylate with respect to specific gender populations.

Race

There is no FDA guidance on the use of Dabrafenib mesylate with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Dabrafenib mesylate in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Dabrafenib mesylate in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Dabrafenib mesylate in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Dabrafenib mesylate in patients who are immunocompromised.

Administration and Monitoring

Administration

Oral

Monitoring

There is limited information regarding Monitoring of Dabrafenib mesylate in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Dabrafenib mesylate in the drug label.

Overdosage

There is limited information regarding Dabrafenib mesylate overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Dabrafenib mesylate Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Dabrafenib mesylate Mechanism of Action in the drug label.

Structure

There is limited information regarding Dabrafenib mesylate Structure in the drug label.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Dabrafenib mesylate in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Dabrafenib mesylate in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Dabrafenib mesylate in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Dabrafenib mesylate in the drug label.

How Supplied

Storage

There is limited information regarding Dabrafenib mesylate Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Dabrafenib mesylate |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Dabrafenib mesylate |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Dabrafenib mesylate in the drug label.

Precautions with Alcohol

Alcohol-Dabrafenib mesylate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

®^[1]

Look-Alike Drug Names

A® — B®^[2]

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

↑ Empty citation (help)
↑ "http://www.ismp.org". External link in |title= (help)

{{#subobject:

 |Page Name=Dabrafenib mesylate
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Dabrafenib mesylate
 |Label Name=Dabrafenib mesylate11.png

}}

{{#subobject:

 |Label Page=Dabrafenib mesylate
 |Label Name=Dabrafenib mesylate11.png

}}

[1] Empty citation (help)

[www.ismp.org-2] "http://www.ismp.org". External link in |title= (help)

[1]

[2]

@@ Line 1: / Line 1: @@
 {{DrugProjectFormSinglePage
 |authorTag={{KS}}
+|genericName=dabrafenib mesylate
 |aOrAn=a
-|hasBlackBoxWarning=Yes
+|drugClass=BRAF Inhibitor
-|adverseReactions=<!--Black Box Warning-->
+|indicationType=treatment
+|indication=[[malignant melanoma]]
+|adverseReactions=[[peripheral edema]], [[alopecia]], [[hyperkeratosis]], [[abdominal pain]], [[constipation]], [[anemia]], [[arthralgia]], [[cough]]
 |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
 |blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
@@ Line 12: / Line 15: @@
 <!--FDA-Labeled Indications and Dosage (Adult)-->
-|fdaLIADAdult======Condition1=====
+|fdaLIADAdult===Indications==
-* Dosing Information
+'''BRAF V600E Mutation-Positive Unresectable or Metastatic Melanoma'''
-:* Dosage
+TAFINLAR® as a single agent is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
-=====Condition2=====
+'''BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma'''
-* Dosing Information
+TAFINLAR, in combination with trametinib, is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test. This indication is based on the demonstration of durable response rate [see Clinical Studies (14.2)]. Improvement in disease-related symptoms or overall survival has not been demonstrated for TAFINLAR in combination with trametinib.
-:* Dosage
+'''Limitation of Use'''
-=====Condition3=====
+TAFINLAR is not indicated for treatment of patients with wild-type BRAF melanoma.
-* Dosing Information
+==Dosing==
-:* Dosage
+'''Recommended Dosing'''
-=====Condition4=====
+* The recommended dosage regimens of TAFINLAR are:
-* Dosing Information
+:*150 mg orally taken twice daily, approximately 12 hours apart, as a single agent
-:* Dosage
+:*150 mg orally taken twice daily, approximately 12 hours apart, in combination with trametinib 2 mg orally taken once daily
-<!--Off-Label Use and Dosage (Adult)-->
+* Continue treatment until disease progression or unacceptable toxicity occurs. Take TAFINLAR as a single agent, or TAFINLAR in combination with trametinib, at least 1 hour before or 2 hours after a meal[see Clinical Pharmacology (12.3)]. Do not take a missed dose of TAFINLAR within 6 hours of the next dose of TAFINLAR. Do not open, crush, or break TAFINLAR capsule.
-<!--Guideline-Supported Use (Adult)-->
+* When administered in combination with trametinib, take the once-daily dose of trametinib at the same time each day with either the morning dose or the evening dose of TAFINLAR.
-|offLabelAdultGuideSupport======Condition1=====
-* Developed by:
+==Dose Modifications==
-* Class of Recommendation:
+For New Primary Cutaneous Malignancies: No dose modifications are required.
-* Strength of Evidence:
+For New Primary Non-Cutaneous Malignancies: Permanently discontinue TAFINLAR in patients who develop RAS mutation-positive non-cutaneous malignancies. If used in combination with trametinib, no dose modifications are required for trametinib in patients who develop non-cutaneous malignancies.
+|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
-* Dosing Information
-:* Dosage
+|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
-=====Condition2=====
-There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
-<!--Non–Guideline-Supported Use (Adult)-->
+|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
-|offLabelAdultNoGuideSupport======Condition1=====
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
-<!--Pediatric Indications and Dosage-->
-<!--FDA-Labeled Indications and Dosage (Pediatric)-->
-|fdaLIADPed======Condition1=====
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
-<!--Off-Label Use and Dosage (Pediatric)-->
 <!--Guideline-Supported Use (Pediatric)-->
-|offLabelPedGuideSupport======Condition1=====
+|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-* Developed by:
-* Class of Recommendation:
-* Strength of Evidence:
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-<!--Non–Guideline-Supported Use (Pediatric)-->
+|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-|offLabelPedNoGuideSupport======Condition1=====
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-<!--Contraindications-->
-|contraindications=* Condition1
-<!--Warnings-->
-|warnings=* Description
-====Precautions====
-* Description
-<!--Adverse Reactions-->
-<!--Clinical Trials Experience-->
 |clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
-=====Body as a Whole=====
-=====Cardiovascular=====
-=====Digestive=====
-=====Endocrine=====
-=====Hematologic and Lymphatic=====
-=====Metabolic and Nutritional=====
-=====Musculoskeletal=====
-=====Neurologic=====
-=====Respiratory=====
-=====Skin and Hypersensitivy Reactions=====
-=====Special Senses=====
-=====Urogenital=====
-=====Miscellaneous=====
-<!--Postmarketing Experience-->
 |postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
-=====Body as a Whole=====
-=====Cardiovascular=====
-=====Digestive=====
-=====Endocrine=====
-=====Hematologic and Lymphatic=====
-=====Metabolic and Nutritional=====
-=====Musculoskeletal=====
-=====Neurologic=====
-=====Respiratory=====
-=====Skin and Hypersensitivy Reactions=====
-=====Special Senses=====
-=====Urogenital=====
-=====Miscellaneous=====
-<!--Drug Interactions-->
-|drugInteractions=* Drug
-:* Description
-<!--Use in Specific Populations-->
-|useInPregnancyFDA=* '''Pregnancy Category'''
 |useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
@@ Line 266: / Line 92: @@
 |administration=* Oral
-* Intravenous
 |monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
-* Description
-<!--IV Compatibility-->
 |IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
-<!--Overdosage-->
-|overdose====Acute Overdose===
-====Signs and Symptoms====
+|structure=
-* Description
-====Management====
+|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
-* Description
-===Chronic Overdose===
+|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
-There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
-<!--Pharmacology-->
+|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
-<!--Drug box 2-->
-|drugBox=<!--Mechanism of Action-->
-|mechAction=*
-<!--Structure-->
+|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
-|structure=*
-: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
-<!--Pharmacodynamics-->
-|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
-<!--Pharmacokinetics-->
-|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
-<!--Nonclinical Toxicology-->
-|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
-<!--Clinical Studies-->
-|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
-<!--How Supplied-->
 |howSupplied=*
-|packLabel=<!--Patient Counseling Information-->
 |fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
-<!--Precautions with Alcohol-->
 |alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
-<!--Brand Names-->
 |brandNames=* ®<ref>{{Cite web | title =  | url = }}</ref>

Dabrafenib mesylate: Difference between revisions

Revision as of 18:02, 30 January 2015

Disclaimer

Overview

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

Dosing

Dose Modifications

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Non–Guideline-Supported Use

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Non–Guideline-Supported Use

Contraindications

Warnings

Adverse Reactions

Clinical Trials Experience

Postmarketing Experience

Drug Interactions

Use in Specific Populations

Pregnancy

Labor and Delivery

Nursing Mothers

Pediatric Use

Geriatic Use

Gender

Race

Renal Impairment

Hepatic Impairment

Females of Reproductive Potential and Males

Immunocompromised Patients

Administration and Monitoring

Administration

Monitoring

IV Compatibility

Overdosage

Pharmacology

Mechanism of Action

Structure

Pharmacodynamics

Pharmacokinetics

Nonclinical Toxicology

Clinical Studies

How Supplied

Storage

Images

Drug Images

Package and Label Display Panel

Patient Counseling Information

Precautions with Alcohol

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

Navigation menu